Whole DNA methylome profiling in lung cancer cells before and after epithelial-to-mesenchymal transition

Diagnostic Pathology

Yun Liu²  Lixing Zhan⁵  Lin He¹  Liming Tao⁵  Di Zhang³  Zhou Zhang³  Xiaomin Niu⁴  Mengyuan Kan⁵  Daizhan Zhou³  Yi Zhou⁵  Fatao Liu⁵ 

[1] Institute of Biomedical Sciences, Fudan University, Shanghai 200032, PR China;Key Laboratory of Molecular Medicine, The Ministry of Education, Department of Biochemistry and Molecular Biology, Fudan University Shanghai Medical College, 138 YiXueYuan RD, Shanghai 200032, PR China;Bio-X Institute, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, PR China;Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, PR China;Institute for Nutritional Sciences, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, 320 Taiyuan RD, Shanghai 200031, PR China

关键词: MSCC;    CGI;    CpG;    Lung cancer;    Epithelial-to-mesenchymal transition (EMT);    DNA methylation;   

Others  :  802119
DOI  :  10.1186/1746-1596-9-66

 received in 2014-01-25, accepted in 2014-03-08,  发布年份 2014

【 摘 要 】

Background

Metastatic lung cancer is one of the leading causes of cancer death. In recent years, epithelial-to-mesenchymal transition (EMT) has been found to contribute to metastasis, as it enables migratory and invasive properties in cancer cells. Previous genome-wide studies found that DNA methylation was unchanged during EMT induced by TGF-β in AML12 cells. In this study, we aimed to discover EMT-related changes in DNA methylation in cancer cells, which are poorly understood.

Methods

We employed a next-generation sequencing-based method, MSCC (methyl-sensitive cut counting), to investigate DNA methylation during EMT in the A549 lung cancer cell line.

Results

We found that methylation levels were highly correlated to gene expression, histone modifications and small RNA expression. However, no differentially methylated regions (DMRs) were found in A549 cells treated with TGF-β for 4 h, 12 h, 24 h and 96 h. Additionally, CpG islands (CGIs) showed no overall change in methylation levels, and at the single-base level, almost all of the CpGs showed conservation of DNA methylation levels. Furthermore, we found that the expression of DNA methyltransferase 1, 3a, 3b (DNMT1, DNMT3a, DNMT3b) and ten-eleven translocation 1 (TET1) was altered after EMT. The level of several histone methylations was also changed.

Conclusions

DNA methylation-related enzymes and histone methylation might have a role in TGF-β-induced EMT without affecting the whole DNA methylome in cancer cells. Our data provide new insights into the global methylation signature of lung cancer cells and the role of DNA methylation in EMT.

Virtual slides

The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1112892497119603 webcite

【 授权许可】

   
2014 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int Du Cancer 2010, 127(12):2893-2917.
• [2]Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, Ma Y, Wang H, Zang W, Zhang G, Zhao G: Analysis of MAT3 gene expression in NSCLC. Diagn Pathol 2013, 8:166.
• [3]Lu Q, Lu S, Huang L, Wang T, Wan Y, Zhou CX, Zhang C, Zhang Z, Li X: The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer. Diagn Pathol 2013, 8:145.
• [4]Xiong Y, Bai Y, Leong N, Laughlin TS, Rothberg PG, Xu H, Nong L, Zhao J, Dong Y, Li T: Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol 2013, 8(1):27.
• [5]Saintigny P, Burger JA: Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 2012, 13(71):287-297.
• [6]Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890.
• [7]Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y, Yu W: miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett 2012, 586:3761-3765.
• [8]Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG, Weiss SJ: Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic breast cancer 1, early onset (BRCA1) repression. Proc Natl Acad Sci USA 2012, 109:16654-16659.
• [9]Sethi S, Macoska J, Chen W, Sarkar FH: Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 2010, 3(1):90-99.
• [10]You JS, Jones PA: Cancer genetics and epigenetics: two sides of the same coin? Cancer cell 2012, 22(1):9-20.
• [11]Jones PA: Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012, 13(7):484-492.
• [12]Suzuki MM, Bird A: DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008, 9(6):465-476.
• [13]Bird AP: CpG-rich islands and the function of DNA methylation. Nature 1986, 321(6067):209-213.
• [14]Antequera F, Bird A: Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA 1993, 90(24):11995-11999.
• [15]Jones PA: The DNA methylation paradox. Trends Genet 1999, 15(1):34-37.
• [16]Cedar H, Bergman Y: Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009, 10(5):295-304.
• [17]Ito S, D’Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y: Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466(7310):1129-1133.
• [18]Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, Oosting J, van Eijk R, Eilers PH, van de Water B, Cornelisse CJ, Cleton-Jansen AM: E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 2006, 94(5):661-671.
• [19]Ke XS, Qu Y, Cheng Y, Li WC, Rotter V, Oyan AM, Kalland KH: Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomic 2010, 11:669.
• [20]McDonald OG, Wu H, Timp W, Doi A, Feinberg AP: Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol 2011, 18(8):867-874.
• [21]Guo JU, Ma DK, Mo H, Ball MP, Jang MH, Bonaguidi MA, Balazer JA, Eaves HL, Xie B, Ford E, Zhang K, Ming GL, Gao Y, Song H: Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci 2011, 14(10):1345-1351.
• [22]Eaves HL, Gao Y: MOM: maximum oligonucleotide mapping. Bioinformatics 2009, 25(7):969-970.
• [23]Katakura Y, Nakata E, Miura T, Shirahata S: Transforming growth factor beta triggers two independent-senescence programs in cancer cells. Biochem Biophys Res Commun 1999, 255(1):110-115.
• [24]Liu J, Hu G, Chen D, Gong AY, Soori GS, Dobleman TJ, Chen XM: Suppression of SCARA5 by Snail1 is essential for EMT-associated cell migration of A549 cells. Oncog 2013, 2:e73.
• [25]Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A: MiR-134/487b/655 cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 2014, 13(2):444-453.
• [26]Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428.
• [27]Siegel PM, Massague J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003, 3(11):807-821.
• [28]Moustakas A, Heldin P: TGFbeta and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta 2014. in press
• [29]Lamouille S, Xu J, Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014, 15(3):178-196.
• [30]Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-Bromage H, Tempst P, Lin SP, Allis CD, Cheng X, Bestor TH: DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448(7154):714-717.
• [31]Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, Temper V, Razin A, Cedar H: Sp1 elements protect a CpG island from de novo methylation. Nature 1994, 371(6496):435-438.
• [32]Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi BZ, Cedar H: DNA methylation represses transcription in vivo. Nature Genet 1999, 22(2):203-206.
• [33]Frank D, Keshet I, Shani M, Levine A, Razin A, Cedar H: Demethylation of CpG islands in embryonic cells. Nature 1991, 351(6323):239-241.
• [34]Hitchins MP, Rapkins RW, Kwok CT, Srivastava S, Wong JJ, Khachigian LM, Polly P, Goldblatt J, Ward RL: Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5′UTR. Cancer cell 2011, 20(2):200-213.
• [35]Hahn MA, Wu X, Li AX, Hahn T, Pfeifer GP: Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks. PloS One 2011, 6(4):e18844.
• [36]Eden S, Hashimshony T, Keshet I, Cedar H, Thorne AW: DNA methylation models histone acetylation. Nature 1998, 394(6696):842.
• [37]Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H: The role of DNA methylation in setting up chromatin structure during development. Nature Genet 2003, 34(2):187-192.
• [38]Zilberman D, Coleman-Derr D, Ballinger T, Henikoff S: Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature 2008, 456(7218):125-129.
• [39]Taberlay PC, Kelly TK, Liu CC, You JS, De Carvalho DD, Miranda TB, Zhou XJ, Liang G, Jones PA: Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell 2011, 147(6):1283-1294.
• [40]Nguyen CT, Gonzales FA, Jones PA: Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res 2001, 29(22):4598-4606.
• [41]Wade PA, Wolffe AP: ReCoGnizing methylated DNA. Nat Struct Biol 2001, 8(7):575-577.
• [42]Rudenko A, Tsai LH: Epigenetic modifications in the nervous system and their impact upon cognitive impairments. Neuropharmacology 2014. in press
• [43]Tempera I, Lieberman PM: Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol 2014. in press
• [44]Ghavifekr Fakhr M, Farshdousti Hagh M, Shanehbandi D, Baradaran B: DNA methylation pattern as important epigenetic criterion in cancer. Genet Res Int 2013, 2013:317569.
• [45]Tokarz P, Blasiak J: Role of DNA methylation in colorectal cancer. Postepy Biochem 2013, 59(3):267-279.
• [46]Sartor MA, Mahavisno V, Keshamouni VG, Cavalcoli J, Wright Z, Karnovsky A, Kuick R, Jagadish HV, Mirel B, Weymouth T, Athey B, Omenn GS: ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics 2010, 26(4):456-463.